Protocol · Autoimmune/Ophthalmological Disorders
Graves' Orbitopathy (Thyroid Eye Disease) Support Protocol
Selenium is the core of this stack, with 3 supporting supplements. Each row gives the amount the protocol lists and the grade our evidence database holds for that supplement in Graves' Orbitopathy (Thyroid Eye Disease) Support.
We are re-verifying the studies cited on protocol pages; only confirmed citations are shown.
The stack
4 supplements · none graded yet
| Grade | Supplement | Amount listed | Why it’s in the stack | Evidence on file | Shop |
|---|---|---|---|---|---|
| Primary stackThe core of this protocol | |||||
| Selenium | Amount listed: 200 mcg daily (selenomethionine) | Antioxidant; reduces orbital inflammation; improves quality of life in mild GO | Not graded yet | ||
| Supporting stackListed as additions to the core | |||||
| Vitamin D | Amount listed: 2,000–4,000 IU daily | Immune modulation; deficiency associated with autoimmune thyroid disease | Not graded yet | ||
| Omega-3 Fatty Acids | Amount listed: 2–3 g EPA+DHA daily | Anti-inflammatory; may support ocular surface health | Not graded yet | ||
| Antioxidant Complex | Amount listed: Vitamin C 500 mg, Vitamin E 400 IU daily | Reduces oxidative stress in orbital tissues | Not graded yet | ||
Shop this protocol
Support alongside medical care. These supplements are not a treatment for Graves' Orbitopathy (Thyroid Eye Disease). If you are being treated for it, talk to your clinician before adding one: supplements can interact with medicines.
Each opens third-party tested products, matched to the dose above where we can.
Links to Fullscript, iHerb or Thorne carry our referral, so we may earn a commission at no extra cost to you. Grades come from the research and never change based on what we earn. Fullscript asks for a free account before it shows its catalog and prices. Full disclosure
How this protocol works
In plain language
Graves' Orbitopathy (GO), also called Thyroid Eye Disease (TED), is an autoimmune condition affecting the muscles and tissues around the eyes. It usually occurs with Graves' disease (hyperthyroidism) but can occur before or after thyroid problems.
SYMPTOMS:
- Mild: Gritty/sandy feeling, watery eyes, light sensitivity, eyelid swelling
- Moderate: Bulging eyes (proptosis), double vision, eye pressure
- Severe: Vision loss (optic nerve compression), corneal exposure
DISEASE PHASES:
- Active phase: Inflammation ongoing (6-24 months)
- Inactive phase: Stable but residual changes may persist
RISK FACTORS:
- Smoking: MAJOR risk factor - makes GO worse, reduces treatment response
- Female sex (though males often more severe)
- Radioactive iodine therapy (can worsen GO)
- Poor thyroid control
CRITICAL: GO requires ophthalmological management. This protocol is SUPPORTIVE ONLY.
MEDICAL TREATMENTS:
- Mild: Lubricating eye drops, sunglasses, selenium
- Moderate-Severe Active: IV corticosteroids, teprotumumab (Tepezza)
- Sight-threatening: Urgent IV steroids, orbital decompression
- Inactive phase: Surgery for proptosis, strabismus, eyelid retraction
MOST IMPORTANT:
- QUIT SMOKING - single most important modifiable factor
- Maintain euthyroid state (normal thyroid levels)
- Sleep with head elevated
- Use lubricating drops frequently
- Wear sunglasses outdoors
Selenium* has strong evidence for mild GO (EUGOGO trial).
Vitamin D* supports immune modulation.
Antioxidants* may help reduce oxidative stress.
Expected timeline: Active phase typically lasts 12-24 months. Selenium shown to improve quality of life within 6 months in mild disease.